American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2024

Evidence of misdiagnosis in administrative claims data for individuals with myasthenia gravis

Social determinants of health are associated with delayed diagnosis in myasthenia gravis

Compliance to daily self-administered subcutaneous zilucoplan in patients with generalized myasthenia gravis: A post hoc analysis of the RAISE-XT study

Efficacy of zilucoplan in patients with generalized myasthenia gravis without prior immunoglobulin or plasma exchange in the RAISE study

Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT

Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT

Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT

Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design

Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study